Nano-hydroxyapatite vs CPP-ACP vs fluoride: the evidence, ranked

Three enamel actives with wildly different amounts of proof behind them. Every review named, every PMID checked against PubMed, every industry funding tie disclosed, including the ones that sit uncomfortably close to my own business.

Three actives compete for the same job on your enamel. Fluoride, the incumbent, in toothpaste, rinse, varnish and in some countries the tap water. Nano-hydroxyapatite, the mineral enamel is mostly made of, sold back to you in particle form. And CPP-ACP, a casein-derived calcium-phosphate complex commercialised as Recaldent and sold mostly through dental practices. Every comparison page you will find on this question ranks them by mechanism, because mechanism stories are easy to tell and flatter whichever ingredient the page is selling.

This one ranks them by evidence instead, which produces a less convenient answer. When you line up the actual systematic reviews and read what they concluded rather than what press releases said they concluded, the gap between fluoride and the other two is not a narrow one. It is the difference between 96 pooled trials and roughly ten small studies too heterogeneous to combine. The mechanism argument for hydroxyapatite is genuinely elegant. The evidence argument is genuinely thin. Both of those are true at once, and a page that only tells you the first half is not informing you.

Every study named below was checked against its PubMed record while writing, and each carries its PMID so you can do the same in about thirty seconds. Where the authors of a review are paid by companies selling the ingredient it reviews, that is stated in the row, not buried. Where a widely repeated claim turned out to have no traceable source, it has been removed from this page rather than softened, and the removals are listed near the end.

The certainty column is the one that matters and the one nobody reproduces. Two ingredients can both be described as "clinically proven" while one rests on 48,804 randomised participants and the other rests on ten small studies its own reviewers refused to pool. That is not a rounding difference. It is the difference between knowing something and hoping it.

Read the funding column next to it and a second pattern appears. Almost every paper making the strong case for hydroxyapatite has an author list containing employees of a company that sells hydroxyapatite. That does not make the findings wrong, and the disclosures are properly made in every case. It does mean the enthusiastic literature and the commercial interest overlap almost perfectly, which is exactly the situation where an independent replication would be worth more than another favourable review. As of this writing there is not one at the scale the fluoride corpus has.

Which is more effective in 2026: nano-hydroxyapatite, CPP-ACP, or fluoride?

Fluoride, by a wide margin, on the only endpoint that counts cavities. The three act on different parts of the same cycle, and the mechanism stories are all defensible. But mechanism is not evidence. Fluoride has 96 pooled randomised trials behind it and a high-certainty grade. CPP-ACP has around a dozen clinical trials and two independent reviews that found it no better than fluoride. Nano-hydroxyapatite has ten small studies its own reviewers declined to pool and a very low certainty grade, with the parity finding holding only under remineralising conditions. Choose fluoride unless something specific rules it out, then choose the alternative that fits the reason.

What does "remineralization" actually mean for enamel?

Enamel is roughly 96 to 97 percent hydroxyapatite by weight. The remaining few percent is water and organic matrix. Hydroxyapatite is a calcium-phosphate crystal with the chemical formula Ca10(PO4)6(OH)2, packed into rod-shaped prisms that give enamel its Mohs hardness of 5, the hardest substance in the human body. The mineral is laid down during tooth development by ameloblasts and never replaced once those cells die. That is the central constraint: enamel cannot grow back the way bone can.

What it can do is mineralize and demineralize across its surface continuously, in both directions, every day. Saliva carries calcium and phosphate ions. When oral pH drops below the critical threshold of 5.5, the equilibrium shifts toward demineralization: hydroxyapatite crystals at the enamel surface dissolve into the saliva film, losing calcium and phosphate ions to the acidic environment. When pH rises back above 5.5 and the saliva film returns to a saturated state, the equilibrium reverses: calcium and phosphate from the saliva precipitate back onto the enamel surface, restoring the lost mineral. The net direction over time, demineralization or remineralization, is what determines whether enamel thins or holds steady.

Coffee sits at pH 4.8. Wine at 3.5. Citrus juice at 2.5. Resting saliva at 7.4. Every meal and every drink is a pH event. The oral cavity bounces between demineralization and remineralization windows dozens of times a day. The dental literature calls the net trajectory the "Stephan curve" for each acid challenge: a sharp pH drop after intake, a slow recovery, and the integrated area under the curve below pH 5.5 as the mineral-loss exposure. The job of a remineralization agent is either to reduce the area under the demineralization curve or to accelerate the remineralization phase that follows, ideally both.

Three intervention families exist. Family one (fluoride) modifies the surface so that the new crystal that forms during remineralization is more acid-resistant than the original. Family two (nano-hydroxyapatite) delivers the actual mineral building blocks directly to the surface, in the same form the enamel is built from, so remineralization happens with imported material instead of waiting for saliva to saturate. Family three (CPP-ACP) keeps calcium and phosphate ions stabilized in soluble form long enough for the saliva film to remain supersaturated, so the natural remineralization curve runs faster and harder. All three move the balance in the right direction. Understanding that they pull on different parts of the curve is the foundation for picking between them.

How does nano-hydroxyapatite work?

The mechanism is almost embarrassingly simple. Enamel is 96 to 97 percent hydroxyapatite. The active ingredient is hydroxyapatite. Milled to a particle size of roughly 20 to 100 nanometers, the active is small enough to penetrate the micro-porous network of demineralized enamel and to fit into the gaps between the surface crystals. Once the particles settle, they integrate into the existing enamel lattice through ionic interactions, then act as nucleation sites for further crystal growth driven by the saliva film's natural calcium and phosphate. The end result is that surface lesions that lost mineral get the same mineral back, in the same crystal form.

A note on the origin story, because this page used to carry it and no longer does. Almost every hydroxyapatite brand, mine included at one point, repeats a version of the tale in which NASA developed the material in the 1970s for astronauts losing bone and tooth mineral, a named researcher is credited, and Japanese licensing follows. I could not verify that chain against a primary source. Not the researcher, not the NASA programme, not the 1993 Japanese approval date. It may well be broadly true; plenty of repeated things are. But a claim that cannot be traced to a document is not evidence, and it has been cut from this page rather than hedged. Judge the ingredient on the trials.

The European regulatory position, by contrast, is a matter of published law. The Scientific Committee on Consumer Safety adopted its opinion on Hydroxyapatite (nano) on 22 March 2023, and Commission Regulation (EU) 2024/858 of 14 March 2024 amended the cosmetics regulation accordingly. The permission is precise: up to 10 percent in toothpaste, up to 0.465 percent in mouthwash. It applies only to rod-shaped particles that are not coated or surface-modified, where at least 95.8 percent by particle number have an aspect ratio below 3 and the remainder do not exceed 4.9. It expressly does not extend to sprayable products, because no inhalation data was supplied to assess that route.

Two things follow that most product pages skip. First, that authorisation is a cosmetics decision covering toothpaste and mouthwash. It is not a blanket EU approval of hydroxyapatite in every oral format, and anyone citing it as one, in either direction, is overreaching. Second, a safety clearance is not an efficacy finding. The SCCS was asked whether the material is safe at those levels, and answered yes with conditions. It was not asked whether it prevents cavities, and did not say so.

Efficacy is where the picture gets uncomfortable for the ingredient. The anchor synthesis is Wierichs, Wolf, Campus and Carvalho, published in Clinical Oral Investigations in April 2022 (PMID 35103837). It found five in vivo and five in situ studies, covering at least 633 teeth in more than 420 patients. It could not run a meta-analysis on the in vivo studies at all, because the designs and outcomes were too heterogeneous. Six of the included studies carried a high risk of bias. Six were funded or published by the manufacturers of the products being tested. The authors graded the evidence very low and wrote that no conclusive statement about efficacy is possible.

The finding inside that review which gets quoted, and the half that gets dropped, deserve to sit next to each other. Under remineralising conditions, nano-hydroxyapatite and sodium fluoride showed the same remineralising potential. That is the sentence you will see on product pages. Under demineralising conditions, sodium fluoride hindered demineralisation and nano-hydroxyapatite did not, performing no differently from a fluoride-free control. That is the sentence you will not. A mouth under acid attack is in the second condition, which is precisely when you want the protection to work.

There is a genuinely stronger case, and it is on a different endpoint. Limeback, Enax and Meyer published an updated systematic review and meta-analysis in Biomimetics in January 2023 (PMID 36648809) covering 44 clinical trials of hydroxyapatite for dentin hypersensitivity. It found a 39.5 percent reduction versus placebo and a 23 percent reduction versus fluoride, with more than half the trials scoring well on GRADE. That is a real result on sensitivity, and it is worth knowing. It is not a caries result, and citing it as one, which happens constantly, is a category error. Two of the three authors are employees of Dr. Kurt Wolff GmbH, which sells hydroxyapatite oral care. They disclosed it; so should anyone quoting them.

The most recent pro-hydroxyapatite synthesis is Pawinska and colleagues in Journal of Dentistry, December 2024 (PMID 39471896), which pooled 5 clinical and 8 in situ trials out of 18 retrieved and concluded that hydroxyapatite works as an anti-caries active in the absence of fluoride. That is a meaningful expansion of the evidence base and should be read as such. It is also an author list that includes two Dr. Kurt Wolff employees, and 13 pooled studies against Cochrane's 96. Both facts are load-bearing.

How does CPP-ACP (Recaldent) work?

CPP-ACP stands for casein phosphopeptide amorphous calcium phosphate. It is a milk-derived ingredient developed by Eric Reynolds and his group at the University of Melbourne in the 1990s, licensed to a manufacturer as Recaldent, and best known in the consumer market as MI Paste from GC America and as the active in Trident White and a handful of Recaldent-branded gums. The mechanism sits in the chemistry of saliva supersaturation: instead of depositing mineral directly, CPP-ACP keeps calcium and phosphate ions soluble and available so the saliva film stays supersaturated long enough to remineralize through natural pathways.

The casein phosphopeptide is a fragment of bovine milk protein, isolated by enzymatic hydrolysis. The peptide binds amorphous calcium phosphate clusters at multiple sites, keeping them in soluble, non-crystalline form and preventing premature precipitation. When the complex hits the enamel surface, the peptide releases the calcium and phosphate into the saliva film at the local interface. The local ion concentration spikes above saturation, and the saliva film can then remineralize subsurface lesions with calcium-phosphate at the same chemical address that hydroxyapatite would normally come from. The casein peptide also acts as a buffer, binding free calcium so it does not precipitate uselessly in the bulk of the saliva.

Two independent systematic reviews have asked the direct question, and both landed in the same place. Raphael and Blinkhorn published in BMC Oral Health in September 2015 (PMID 26408042), screening 7,576 records down to 12 eligible clinical trials. Their finding: no significant benefit from CPP-ACP paste over brushing with a fluoride toothpaste for preventing early caries, a tendency toward benefit for white-spot regression in orthodontic patients on limited-quality evidence, and no evidence that the fluoride-added formulation beat the plain one. One caveat belongs with that: the lead author lists employment with Colgate-Palmolive, which competes with the reviewed product. A negative result from a competitor-affiliated author deserves the same scepticism as a positive one from a manufacturer-affiliated author.

Indrapriyadharshini and colleagues, writing independently in the Indian Journal of Dental Research in 2018 (PMID 30127201), reached a mirror-image conclusion from 12 randomised trials: CPP-ACP showed high-level evidence of remineralising potential on both naturally occurring and post-orthodontic white-spot lesions, compared with placebo, fluoridated toothpaste and fluoride varnish, without a statistically significant difference between them. Read carefully, those two reviews agree. CPP-ACP does something. It does not do more than fluoride does.

The most current picture comes from Hussain and colleagues in BMC Oral Health, February 2026 (PMID 41723426), a network meta-analysis of 70 randomised trials and 4,634 participants. For reducing white-spot severity, CPP-ACP ranked among the most effective agents alongside self-assembling peptide, NovaMin and nano-agents. For preventing white spots forming at all, fluoride varnish came out on top. Notably, no intervention in the entire network significantly reduced lesion size, and the authors flag sparse networks and moderate risk of bias. This is the strongest current evidence for CPP-ACP, and it is a treatment result rather than a prevention one.

The constraint that defines CPP-ACP's commercial ceiling is the casein source. The active is derived from bovine milk casein, which means anyone with a true milk-protein allergy (IgE-mediated, not lactose intolerance, which is a separate enzyme issue) must avoid it. The manufacturer flags this on every product insert. Beyond the allergy contraindication, the cost structure is high: clinical-channel pricing, smaller scale, and a more complex extraction process keep CPP-ACP at the top of the cost ladder versus nano-HAp or fluoride. That cost has kept CPP-ACP largely confined to the clinical adjunct lane rather than the everyday-consumer lane, which is why most people have never heard of it even if they use a Trident or have had a fluoride varnish appointment recently.

How does fluoride work, and why is it still the dental standard?

Fluoride is the default for a reason that has nothing to do with inertia. It is cheap, it is well understood, it is endorsed by the American Dental Association and the NHS, and it holds the largest body of caries-prevention evidence in dentistry by an enormous margin.

The specific numbers are worth stating because they set the bar every challenger has to clear. Walsh, Worthington, Glenny, Marinho and Jeroncic published the current Cochrane review, Fluoride toothpastes of different concentrations for preventing dental caries, CD007868, in March 2019 (PMID 30829399). It includes 96 studies published between 1955 and 2014. Eighty-five of those, covering 48,804 randomised participants with 40,066 evaluated, addressed the immature permanent dentition. Eighty-one entered a network meta-analysis spanning 21 comparisons across seven fluoride concentrations, with most follow-up periods running 36 months.

The certainty grades matter as much as the effect sizes. There was high and moderate certainty evidence that 1,000 to 1,250 ppm and 1,450 to 1,500 ppm fluoride toothpastes reduce caries increment compared with non-fluoride toothpaste. The concentration-response relationship is real but modest at the top end: 1,450 to 1,500 ppm only slightly outperformed 1,000 to 1,250 ppm, on moderate-certainty evidence, and 1,055 versus 550 ppm came out similar. Cochrane also graded much of the remaining network as low certainty, which is a level of self-criticism the challenger literature rarely matches.

The mechanism is surface modification rather than mineral deposit. When fluoride ions reach the enamel surface, they displace the hydroxide group at the apex of the apatite crystal, producing fluorapatite (Ca10(PO4)6F2). Fluorapatite has two properties that make it useful. First, it is harder than hydroxyapatite at the crystal-lattice level. Second, and more important, it has a lower critical pH: hydroxyapatite begins dissolving around pH 5.5, fluorapatite holds out down to around pH 4.5. That one-unit pH shift is huge in saliva chemistry because each pH unit is a tenfold change in hydrogen-ion concentration. A surface that has converted to fluorapatite resists acid attacks an order of magnitude longer than the same surface without fluoride.

The second mechanism, often underweighted in consumer guides, is antimicrobial. Fluoride ions inhibit several bacterial enzymes used in glucose metabolism by Streptococcus mutans and related cariogenic streptococci. That direct antibacterial effect, on top of the acid-resistance shift, is part of why fluoride remains so effective in real-world cavity prevention even in mouths where the surface chemistry alone would not explain the size of the effect.

The trade-off is well documented. Fluoride has a defined upper-intake limit. Below that limit it is safe and effective. Above it, dental fluorosis appears as developmental enamel mottling in children whose teeth are still forming. The CDC sets community water fluoridation at 0.7 ppm in the United States, and adult toothpaste typically carries 1,000 to 1,500 ppm. Which type of fluoride salt is in the tube changes the picture too, and we cover that separately in stannous versus sodium fluoride. Adults swallow small amounts of toothpaste during brushing; the public-health math works because total intake from food, water and toothpaste stays well below the threshold for systemic effect in adults. For children under six, the math is closer, which is why pediatric guidance limits paste volume and supervises brushing. The AAPD has clear age-banded dosing protocols for exactly this reason.

The other trade-off is what fluoride does not do. It does not deposit new mineral. It modifies the existing surface, and it makes the remineralization that does occur produce a more acid-resistant crystal. If your enamel is already substantially eroded, fluoride helps the surface that remains hold its line; it does not rebuild what is gone. That is the gap that the apatite and CPP-ACP categories fill, and it is the reason daily routines that combine fluoride with one of the deposit-style actives now appear in EU and Japanese clinician guidance, especially for adolescents and high-risk adults.

Head-to-head: nano-HAp vs fluoride trials

Trial design for a remineralization head-to-head usually runs one of three protocols. In-situ slab studies place small enamel chips in dental appliances worn by volunteers, exposed to standardized acid challenges and then to the test agents. In-vivo white-spot lesion trials, mostly in orthodontic populations, measure lesion depth and fluorescence over weeks. And micro-hardness recovery trials measure the surface property that correlates most directly with structural integrity. Each protocol catches a different facet of the question.

The honest head-to-head verdict rests on the Wierichs 2022 review (PMID 35103837), and it is conditional rather than clean. Under remineralising conditions, the in situ studies showed nano-hydroxyapatite and sodium fluoride with the same remineralising potential. Under demineralising conditions, sodium fluoride hindered demineralisation while nano-hydroxyapatite did not, and did not differ from the fluoride-free control. Parity in the favourable half of the cycle, absence in the unfavourable half. That is the actual finding, and quoting only the first sentence is the single most common misrepresentation in this category.

One frequently cited in situ trial is worth reading correctly because it is routinely inflated. Amaechi and colleagues, BDJ Open 2019 (PMID 31839988), compared a 10 percent hydroxyapatite toothpaste against a 500 ppm amine-fluoride toothpaste using enamel blocks in intra-oral appliances worn by 30 adults. That is a genuine study and a genuinely interesting result. It is also 30 adults, not sixty adolescents; enamel blocks in appliances, not teeth in mouths; and 500 ppm fluoride, not the 1,450 ppm that most adult toothpaste actually contains. Earlier versions of this page described that trial with the wrong population and the wrong comparator. Both have been corrected.

Three caveats hold across the whole head-to-head literature. First, the endpoints are surrogates. Lesion depth, fluorescence and micro-hardness are proxies for cavities, not cavities, and the Cochrane fluoride corpus measures the real thing over 36 months. Second, the horizons are short, mostly weeks. Third, and least discussed, the comparator concentrations are often chosen in ways that flatter the challenger, as the 500 ppm example shows. None of this makes hydroxyapatite useless. It makes "matches fluoride" a claim that needs its conditions attached every single time.

The defensible 2026 summary: on surrogate endpoints under favourable conditions, nano-hydroxyapatite performs comparably to fluoride in a small number of low-certainty studies. On counted cavities over years, fluoride is the only one of the two with an answer at all. If you want the longer version of why most dentists still say this out loud, we wrote it up in why dentists don't recommend hydroxyapatite.

Head-to-head: CPP-ACP vs fluoride trials

The CPP-ACP versus fluoride literature is older and better populated than the hydroxyapatite set, because CPP-ACP reached the clinical market roughly a decade earlier in the West. The cleanest single trial is Bröchner and colleagues, Clinical Oral Investigations 2011 (PMID 20383545). Sixty adolescents with visible white-spot lesions at debonding were randomised to daily topical 10 percent CPP-ACP or to brushing with standard fluoride toothpaste, for four weeks, with quantitative light-induced fluorescence as the endpoint across 327 lesions.

Both groups improved significantly against baseline. Neither beat the other. Mean lesion area fell 58 percent in the CPP-ACP arm and 26 percent in the fluoride arm, and that gap did not reach significance at p = 0.06. The authors' own conclusion is the useful sentence: the improvement was not superior to the natural regression seen with daily fluoride toothpaste. A near-miss p-value in a sixty-patient trial is a reason to run a bigger trial, not a reason to claim a win, and this page previously described that study with the wrong year, an author who is not on it, and a conclusion it does not support.

Zoom out to the pooled orthodontic evidence and fluoride holds its ground. Höchli and colleagues in the European Journal of Orthodontics 2017 (PMID 27907894) meta-analysed 20 randomised studies covering 942 patients, average age 16.2, with a mean of 8.2 white-spot lesions each. Monthly fluoride varnish came out as the best supplement for improving lesion area and enamel fluorescence, both on high-quality evidence, followed by fluoride film. CPP-ACP creams were in the comparison set and did not lead it. The 2026 Hussain network meta-analysis later ranked CPP-ACP highly for lesion severity while still putting fluoride varnish first for prevention.

On post-bleaching sensitivity, a correction is owed. This page previously cited a 2014 randomised trial of 60 post-bleaching patients showing CPP-ACP beating a fluoride rinse on visual-analogue sensitivity scores. I could not locate that trial in PubMed while re-checking this article, and it has been removed rather than left in with softer wording. Dental practices do commonly hand out CPP-ACP paste around whitening appointments, and the tubule-occlusion rationale is plausible, but "clinicians do this" is a description of practice, not a citation. If you want an evidence-backed sensitivity option, the hydroxyapatite meta-analysis discussed earlier is the one with 44 trials behind it.

The caveat that has dogged CPP-ACP for two decades is the cost-and-channel structure. The active is more expensive than either nano-HAp or fluoride at scale. The product line is largely sold through dental offices rather than over-the-counter. The casein-allergy contraindication limits the addressable market. And the consumer-side awareness of the ingredient is low: most people who chew a Trident White have never heard of Recaldent and could not tell you what the active is. None of that takes away from the clinical evidence; it does explain why CPP-ACP has stayed in the adjunct lane while fluoride and nano-HAp have grown into the everyday-consumer lane.

The defensible 2026 summary is: CPP-ACP performs at parity with fluoride for orthodontic white-spot lesions across two independent systematic reviews, ranks near the top for reducing existing lesion severity in the 2026 network meta-analysis, and has no comparable body of evidence on general caries incidence. It is a reasonable adjunct alongside fluoride in a specific clinical situation. It is not a substitute for fluoride, and neither review that examined the fluoride-added version found it superior to the plain one.

The triple comparison: when each makes sense

The cleanest way to read the three-way comparison is by mechanism slot. Each active fills a different role on the demineralization-remineralization curve. Fluoride changes the equilibrium so that the surface that survives the acid attack ends up harder and more resistant. Nano-hydroxyapatite delivers the actual mineral that gets laid down during the remineralization phase. CPP-ACP keeps the calcium and phosphate ions available in soluble form so the remineralization phase runs faster and harder. The three actives are not three answers to the same question; they are three actives doing three different jobs.

The tempting next step is to say combinations therefore beat single actives, and the evidence does not support that as a general rule. Raphael and Blinkhorn looked specifically at whether adding fluoride to CPP-ACP improved on CPP-ACP alone and found no evidence that it did. The 2026 network meta-analysis found fluoride combinations effective but did not show them beating fluoride varnish for prevention. Complementary mechanisms are a good reason to expect additive effects; they are not the same thing as having measured one. Stacking two actives is defensible on cost-benefit grounds if both are cheap and safe, which is a different argument from "the trials show it works better."

A useful frame is the order in which to layer the three. Fluoride toothpaste twice a day is the foundation for most adults and almost all children. A nano-HAp daily delivery vehicle (gum, lozenge, rinse) is the second layer that addresses the long gap between brushings, when the surface-armor effect of fluoride does not include new mineral deposit. CPP-ACP enters the stack when there is a specific clinical use case: orthodontic white-spot management, post-bleaching sensitivity, or a high-risk dry-mouth patient. Outside those use cases, the cost-benefit math rarely justifies CPP-ACP as a third daily layer.

Practical buyer's grid: how to pick for your situation

We maintain a public, sourced comparison of all 8 hydroxyapatite gums (dose, price, transparency): see the hydroxyapatite gum database →

The trial literature is what it is, but the buying decision happens in a real bathroom on a real budget. Below is a working buyer's grid that translates the chemistry and the trial outcomes into product choices, organized by the question the buyer is actually trying to answer.

If your main concern is cost

Fluoride toothpaste twice a day, at the 1,000 to 1,500 ppm concentration band, is the cheapest evidence-backed routine in this entire category. A quality tube costs EUR 2 to 6 and lasts about a month. The active is the most studied in dentistry, the population-scale caries-reduction data is unmatched, and there is no swallowing concern at the recommended brushing volumes for adults. If budget is the binding constraint, the answer starts and ends here.

If your main concern is daily-use swallow safety

Hydroxyapatite. The active is the same mineral your enamel is largely built from, no oral-care regulator has set an upper daily intake for it, and the EU wrote its safety limits into cosmetics law in 2024. Where the swallow profile is the binding constraint, this is the cleanest answer. Be honest with yourself about what you are optimising for, though: you are buying a better safety margin, not a better cavity record, and if your caries risk is high that is the wrong thing to optimise.

If your main concern is sensitivity

Hydroxyapatite has the largest pooled dataset on this endpoint: 44 clinical trials in Limeback 2023, a 39.5 percent reduction versus placebo and 23 percent versus fluoride. Treat the manufacturer employment on that author list as a reason to discount the effect size somewhat, not a reason to dismiss 44 trials. CPP-ACP paste is what most practices hand out after a whitening appointment, and it may well help, but we could not verify a pooled trial putting it ahead of fluoride for sensitivity, so it goes in as clinical custom rather than as evidence.

If your main concern is the hours between brushings

A nano-HAp delivery vehicle that fits the hours when toothpaste is not in your mouth. Gum is the highest-frequency option (one piece after every meal or coffee adds five to seven mineral-deposit windows to the day). Lozenges and mouthwash deliver less frequent but higher-concentration exposure. The right pick depends on what you will actually use. A gum that pairs nano-HAp with xylitol covers two layers at once: mineral deposit during chewing, plus the saliva-flow-and-bacterial-suppression effect of xylitol that addresses the bacterial side of the cavity equation. For a side-by-side look at what specific products actually put on the label, our label-by-label check of remineralizing gums breaks down the options.

If your main concern is an adolescent in fixed appliances

Ask the orthodontist about fluoride varnish first. That is the intervention that came out top in both pooled analyses of this exact population, Höchli 2017 on treating lesions and Hussain 2026 on preventing them, and it is applied in the chair rather than bought off a shelf. CPP-ACP paste is a reasonable daily adjunct on top of it, with the caveat that Bröchner's randomised trial found it no better than ordinary fluoride toothpaste over four weeks. Anything you add at home is a supplement to the professional protocol, not a replacement for it.

Frequently asked questions